XML 18 R8.htm IDEA: XBRL DOCUMENT

Going Concern	6 Months Ended
Aug. 31, 2020
Going Concern [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. If the Company is unable to generate profits on a sustained basis and is unable to continue to obtain financing for its working capital requirements, it may have to curtail its business sharply or cease business altogether. Substantial additional capital resources will be required to fund continuing expenditures related to our research, development, manufacturing and business development activities. The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis, to retain its current financing, to obtain additional financing, and ultimately to attain profitability. Beginning with the second quarter of fiscal year 2020, we increased operations of our AuraGen^®/VIPER business and revenue for the three and six-months ended August 31, 2020 was $5,000 and $53,633, respectively, as compared to $348,075 of revenue in the comparable periods of Fiscal 2020.

Going Concern

6 Months Ended

Aug. 31, 2020

NOTE 2 – GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The unaudited condensed financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

If the Company is unable to generate profits on a sustained basis and is unable to continue to obtain financing for its working capital requirements, it may have to curtail its business sharply or cease business altogether.

Substantial additional capital resources will be required to fund continuing expenditures related to our research, development, manufacturing and business development activities. The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis, to retain its current financing, to obtain additional financing, and ultimately to attain profitability.

Beginning with the second quarter of fiscal year 2020, we increased operations of our AuraGen^®/VIPER business and revenue for the three and six-months ended August 31, 2020 was $5,000 and $53,633, respectively, as compared to $348,075 of revenue in the comparable periods of Fiscal 2020.